USPTO trademark

SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT

Awaiting publicationUSPTOWord and designClass 5

"SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT" is a word and design mark owned by Axsome Therapeutics, Inc., filed at the USPTO on September 2, 2026. It is waiting to be published and covers class 5 (Pharmaceuticals).

View Axsome Therapeutics, Inc. portfolioGet this data via the API
Official USPTO record
SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT trademark as filed
As filed with the USPTO
Status
Awaiting publication
Since October 15, 2026
Filed
September 2, 2026
Registered
Not yet
Expires
Not recorded
Application no.
50087189
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word and design
1 class
Ownership

Who owns SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Axsome Therapeutics, Inc.

AXSM · New York, United States

150 trademarks in the portfolioView company

Representative

Brent A. Johnson

Procopio, Cory, Hargreaves & Savitch LLP

Goods and services

What the mark covers

The products and services SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT is filed for, grouped by Nice class.

  • Medicated and pharmaceutical preparations for use in connection with smoking cessation; medications for reducing or eliminating smoking and the urge to smoke.

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Approved for pub - principal register
  2. Notification of examiners amendment e-mailed
  3. Examiner's amendment entered
  4. Examiners amendment e-mailed
  5. Examiners amendment -written
  6. Assigned to examiner
  7. New application office supplied data entered
  8. Application filing receipt mailed
  9. New application entered
FAQ

About SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT

Who owns the trademark "SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT"?

The USPTO trademark "SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT" (application 50087189) is owned by Axsome Therapeutics, Inc.

What is the status of "SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT"?

Its status at the USPTO is: awaiting publication.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_01a0676a-ae74-7680-81fe-90ae61fab952
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_01a0676a-ae74-7680-81fe-90ae61fab952",
  "object": "trademark",
  "mark_text": "SUMMIT STUDYING NMDA AND SIGMA-1 IN SMOKING CESSATION TREATMENT",
  "status": {
    "primary": "pending",
    "stage": "pending_publication"
  },
  "office_code": "US",
  "application_number": "50087189",
  "filing_date": "2026-09-02",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Axsome Therapeutics, Inc.",
      "entity_id": "ent_019ebba6-3220-71b6-8fee-f721d26ca090"
    }
  ]
}